Opinion|Videos|June 5, 2024
Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
Advertisement
Video content above is prompted by the following question(s):
- Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Employers With Claims Data Access Take More Cost Action, Survey Finds
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5